Cargando…
Antagonistic Antiviral Activity between IFN-Lambda and IFN-Alpha against Lethal Crimean-Congo Hemorrhagic Fever Virus In Vitro
BACKGROUND AND AIMS: Crimean Congo Hemorrhagic fever virus (CCHFV) is the causative agent of Crimean-Congo hemorrhagic fever, a severe disease with a mortality rate of around 30% in humans. Previous studies demonstrate that pre-treatment with type I IFNs have an antiviral effect against CCHFV, while...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333211/ https://www.ncbi.nlm.nih.gov/pubmed/25693189 http://dx.doi.org/10.1371/journal.pone.0116816 |
_version_ | 1782357995475173376 |
---|---|
author | Bordi, Licia Lalle, Eleonora Caglioti, Claudia Travaglini, Damiano Lapa, Daniele Marsella, Patrizia Quartu, Serena Kis, Zoltan Arien, Kevin K. Huemer, Hartwig P. Meschi, Silvia Ippolito, Giuseppe Di Caro, Antonino Capobianchi, Maria R. Castilletti, Concetta |
author_facet | Bordi, Licia Lalle, Eleonora Caglioti, Claudia Travaglini, Damiano Lapa, Daniele Marsella, Patrizia Quartu, Serena Kis, Zoltan Arien, Kevin K. Huemer, Hartwig P. Meschi, Silvia Ippolito, Giuseppe Di Caro, Antonino Capobianchi, Maria R. Castilletti, Concetta |
author_sort | Bordi, Licia |
collection | PubMed |
description | BACKGROUND AND AIMS: Crimean Congo Hemorrhagic fever virus (CCHFV) is the causative agent of Crimean-Congo hemorrhagic fever, a severe disease with a mortality rate of around 30% in humans. Previous studies demonstrate that pre-treatment with type I IFNs have an antiviral effect against CCHFV, while established CCHFV infection is almost insensitive to subsequent IFN-α treatment. No data concerning type III IFNs antiviral activity against CCHFV are available so far. The aim of the present study was to explore the capability of IFN-λ1 to inhibit the replication of CCHFV and the possible synergism/antagonism between IFN-α and IFN-λ1 both in the inhibition of CCHFV replication and in the activation of intracellular pathways of IFN response. METHODS: Human A549 and HuH7 cells were treated with increasing amounts of IFN-λ1, or IFN-α or a combination of them, infected with CCHF; the extent of virus yield inhibition and the induction of MxA and 2’-5’OAS mRNA was measured. RESULTS AND CONCLUSIONS: Our study pointed out that type III IFN possess an antiviral activity against CCHFV, even if lower than type I IFN. Moreover, a clear antagonism between IFN-λ and IFN–α was observed in both cell lines (A549 and HuH7 cells), in terms of antiviral effect and activation of pivotal ISGs, i.e. MxA and 2’-5’OAS. Elucidating the interplay between type I and III IFNs will help to better understand innate defence mechanisms against viral infections and may provide novel scientific evidence for a more rational planning of available and future treatments, particularly against human diseases caused by high concern viruses. |
format | Online Article Text |
id | pubmed-4333211 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-43332112015-02-24 Antagonistic Antiviral Activity between IFN-Lambda and IFN-Alpha against Lethal Crimean-Congo Hemorrhagic Fever Virus In Vitro Bordi, Licia Lalle, Eleonora Caglioti, Claudia Travaglini, Damiano Lapa, Daniele Marsella, Patrizia Quartu, Serena Kis, Zoltan Arien, Kevin K. Huemer, Hartwig P. Meschi, Silvia Ippolito, Giuseppe Di Caro, Antonino Capobianchi, Maria R. Castilletti, Concetta PLoS One Research Article BACKGROUND AND AIMS: Crimean Congo Hemorrhagic fever virus (CCHFV) is the causative agent of Crimean-Congo hemorrhagic fever, a severe disease with a mortality rate of around 30% in humans. Previous studies demonstrate that pre-treatment with type I IFNs have an antiviral effect against CCHFV, while established CCHFV infection is almost insensitive to subsequent IFN-α treatment. No data concerning type III IFNs antiviral activity against CCHFV are available so far. The aim of the present study was to explore the capability of IFN-λ1 to inhibit the replication of CCHFV and the possible synergism/antagonism between IFN-α and IFN-λ1 both in the inhibition of CCHFV replication and in the activation of intracellular pathways of IFN response. METHODS: Human A549 and HuH7 cells were treated with increasing amounts of IFN-λ1, or IFN-α or a combination of them, infected with CCHF; the extent of virus yield inhibition and the induction of MxA and 2’-5’OAS mRNA was measured. RESULTS AND CONCLUSIONS: Our study pointed out that type III IFN possess an antiviral activity against CCHFV, even if lower than type I IFN. Moreover, a clear antagonism between IFN-λ and IFN–α was observed in both cell lines (A549 and HuH7 cells), in terms of antiviral effect and activation of pivotal ISGs, i.e. MxA and 2’-5’OAS. Elucidating the interplay between type I and III IFNs will help to better understand innate defence mechanisms against viral infections and may provide novel scientific evidence for a more rational planning of available and future treatments, particularly against human diseases caused by high concern viruses. Public Library of Science 2015-02-18 /pmc/articles/PMC4333211/ /pubmed/25693189 http://dx.doi.org/10.1371/journal.pone.0116816 Text en © 2015 Bordi et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Bordi, Licia Lalle, Eleonora Caglioti, Claudia Travaglini, Damiano Lapa, Daniele Marsella, Patrizia Quartu, Serena Kis, Zoltan Arien, Kevin K. Huemer, Hartwig P. Meschi, Silvia Ippolito, Giuseppe Di Caro, Antonino Capobianchi, Maria R. Castilletti, Concetta Antagonistic Antiviral Activity between IFN-Lambda and IFN-Alpha against Lethal Crimean-Congo Hemorrhagic Fever Virus In Vitro |
title | Antagonistic Antiviral Activity between IFN-Lambda and IFN-Alpha against Lethal Crimean-Congo Hemorrhagic Fever Virus In Vitro
|
title_full | Antagonistic Antiviral Activity between IFN-Lambda and IFN-Alpha against Lethal Crimean-Congo Hemorrhagic Fever Virus In Vitro
|
title_fullStr | Antagonistic Antiviral Activity between IFN-Lambda and IFN-Alpha against Lethal Crimean-Congo Hemorrhagic Fever Virus In Vitro
|
title_full_unstemmed | Antagonistic Antiviral Activity between IFN-Lambda and IFN-Alpha against Lethal Crimean-Congo Hemorrhagic Fever Virus In Vitro
|
title_short | Antagonistic Antiviral Activity between IFN-Lambda and IFN-Alpha against Lethal Crimean-Congo Hemorrhagic Fever Virus In Vitro
|
title_sort | antagonistic antiviral activity between ifn-lambda and ifn-alpha against lethal crimean-congo hemorrhagic fever virus in vitro |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333211/ https://www.ncbi.nlm.nih.gov/pubmed/25693189 http://dx.doi.org/10.1371/journal.pone.0116816 |
work_keys_str_mv | AT bordilicia antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro AT lalleeleonora antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro AT caglioticlaudia antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro AT travaglinidamiano antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro AT lapadaniele antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro AT marsellapatrizia antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro AT quartuserena antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro AT kiszoltan antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro AT arienkevink antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro AT huemerhartwigp antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro AT meschisilvia antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro AT ippolitogiuseppe antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro AT dicaroantonino antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro AT capobianchimariar antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro AT castilletticoncetta antagonisticantiviralactivitybetweenifnlambdaandifnalphaagainstlethalcrimeancongohemorrhagicfevervirusinvitro |